Ani Pharmaceuticals (ANIP) Cash from Financing Activities (2010 - 2026)

Ani Pharmaceuticals has reported Cash from Financing Activities for 17 years, with the latest figure at -$21.6 million in Q1 2026.

• Quarterly Cash from Financing Activities fell 118.21% year-over-year to -$21.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$21.7 million (down 107.88% YoY) and the FY2025 annual result came in at -$9.9 million, down 103.75% from the prior year.
• Cash from Financing Activities eased to -$21.6 million in Q1 2026 per ANIP's latest filing, from -$4.6 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $291.0 million in Q3 2024 and troughed at -$21.6 million in Q1 2026.
• A 5-year average of $17.4 million and a median of -$1.7 million in 2025 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities sank 2246.06% in 2023, then soared 7650.47% in 2024.
• Over 5 years, Cash from Financing Activities stood at -$508000.0 in 2022, then tumbled by 2246.06% to -$11.9 million in 2023, then surged by 58.83% to -$4.9 million in 2024, then advanced by 5.52% to -$4.6 million in 2025, then plunged by 366.26% to -$21.6 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$21.6 million, -$4.6 million, and $6.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.